Clinical trials: Coronary Artery Occlusion
Coronary Artery Disease
Simplified Anti-Thrombotic Therapy for FFR
Despite the routine use of procedural anti-coagulation and anti-platelet therapy for FFR calculation, no study has evaluated the optimal anti-thrombotic regimen in patients undergoing FFR.
- Trial name
- SMART-FFR (NCT02384070)
- Testing
- FFR, Aspirin, Clopidogrel
- Volunteers
- 300 people
- Sponsor
- Odessa Heart Institute
Cardiovascular Diseases
A Study of AMR101 to Evaluate Its Ability to Reduce Cardiovascular Events in High-Risk Patients With Hypertriglyceridemia and on Statin
AMR101 (icosapent ethyl [ethyl-EPA]) is a highly purified ethyl ester of eicosapentaenoic acid (EPA) developed by Amarin Pharma Inc.
- Trial name
- REDUCE-IT (NCT01492361)
- Testing
- AMR101, Statin therapy
- Where
- 410 sites in United States, Australia and 9 more
- Volunteers
- 8,179 people
- Sponsor
- Amarin Pharma Inc.
Coronary Artery Disease
Observational Study of OCT in a Patients Undergoing FFR
The purpose of this study is to define and evaluate optical coherence tomography (OCT) stent guidance parameters through prospective data collection in percutaneous coronary intervention (PCI) procedures of de novo lesions.
- Trial name
- ILUMIEN I (NCT01663896)
- Testing
- OCT stent guidance
- Where
- 36 sites in United States, Australia and 12 more
- Volunteers
- 418 people
- Sponsor
- Abbott Medical Devices
Coronary Artery Disease
Intravenous Regadenoson Versus Intravenous Adenoscan® for Fractional Flow Reserve (FFR)
The purpose of this study is to demonstrate that intravenous regadenoson is equivalent to intravenous Adenoscan® for the physiological assessment of intermediate coronary lesions.
- Trial name
- NCT01482169
- Testing
- FFR Measurement with IV Adenoscan® then with Regadenoson
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- Ochsner Health System
Chronic Kidney Disease (CKD), Type 2 Diabetes Mellitus (T2DM)
Impact of Chronic Kidney Disease on Clopidogrel Effects in Diabetes Mellitus
Patients with diabetes mellitus (DM) and chronic kidney disease (CKD) are at increased risk of atherothrombotic events. Clopidogrel is the most widely used platelet P2Y12 receptor inhibitor in patients with coronary artery…
- Conditions
- Chronic Kidney Disease (CKD), Type 2 Diabetes Mellitus (T2DM), Coronary Artery Disease (CAD)
- Trial name
- NCT03774394
- Testing
- Clopidogrel, Clopidogrel active metabolite
- Where
- United States
- Volunteers
- 61 people
- Sponsor
- University of Florida
Coronary Artery Disease
The Medtronic RESOLUTE US Clinical Trial
The objective of the study is to assess the safety and effectiveness of the Resolute Zotarolimus-Eluting Coronary Stent System for the treatment of de novo lesions in native coronary arteries with a reference vessel diameter…
- Trial name
- R-US (NCT00726453)
- Testing
- Resolute Zotarolimus-Eluting Coronary Stent
- Where
- United States
- Volunteers
- 1,516 people
- Sponsor
- Medtronic Vascular
Coronary Artery Disease
The PLATINUM Clinical Trial to Assess the PROMUS Element Stent System for Treatment of De Novo Coronary Artery Lesions in Small Vessels
The purpose of this study is to evaluate the safety and effectiveness of the PROMUS Element™ Everolimus-Eluting Coronary Stent System for the treatment of patients with up to 2 de novo atherosclerotic coronary artery lesions.
- Trial name
- PLATINUM SV (NCT01498692)
- Testing
- PROMUS Element Coronary Stent System
- Where
- 23 sites in United States, Australia and 4 more
- Volunteers
- 94 people
- Sponsor
- Boston Scientific Corporation
Coronary Artery Disease (CAD)
Evaluation of M118 in Percutaneous Coronary Intervention (EMINENCE)
The primary objective is to evaluate the safety and feasibility of using M118 as an anticoagulant in the target population of subjects with stable coronary artery disease (CAD) undergoing percutaneous coronary intervention (PCI).
- Trial name
- EMINENCE (NCT00543400)
- Testing
- M118, Unfractionated Heparin
- Where
- 44 sites in United States, Canada
- Volunteers
- 503 people
- Sponsor
- Momenta Pharmaceuticals, Inc.
Coronary Artery Disease
Aspirin Resistance in Coronary Artery Disease
The purpose of this study is to evaluate possible mechanisms of aspirin resistance at a molecular level in aspirin-treated patients with coronary artery disease.
- Trial name
- NCT00753935
- Testing
- enteric-coated aspirin, Chewable aspirin
- Where
- United States
- Volunteers
- 92 people
- Sponsor
- Vanderbilt University
Ischemic Heart Disease, Coronary Artery Disease
Assessment of Myocardial Ischemic-Reperfusion Injury During Off- and On- Pump CABG
Assessment of myocardial ischemic-reperfusion injury during off- and on- pump CABG.
- Conditions
- Ischemic Heart Disease, Coronary Artery Disease, Ischemic Reperfusion Injury, CABG
- Trial name
- NCT03050489
- Testing
- On-Pump CABG., Off-Pump CABG., BH-CABG MSC.
- Where
- Russia
- Volunteers
- 336 people
- Sponsor
- St. Petersburg State Pavlov Medical University
Atherothrombosis
Pharmacogenomics of Antiplatelet Response - II (PARes-II)
This clinical trial is examining the effect of 4-week aspirin therapy on platelet transcriptome in persons at high-risk for myocardial infarction or stroke due to family history of early-onset coronary artery disease.
- Trial name
- PARes-II (NCT01894555)
- Testing
- Aspirin
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- Johns Hopkins University
Coronary Artery Disease
Screening For Asymptomatic Obstructive Coronary Artery Disease Among High-Risk Diabetic Patients Using CT Angiography, Following Core 64
Patients with a known history of diabetes mellitus and no prior documented evidence of cardiovascular disease will be evaluated for inclusion in the study.
- Trial name
- faCTor-64 (NCT00488033)
- Testing
- CT Angiography
- Where
- United States
- Volunteers
- 900 people
- Sponsor
- Intermountain Health Care, Inc.
Coronary Artery Disease
The Influence of Smoking Status on Prasugrel and Clopidogrel Treated Subjects Taking Aspirin and Having Stable Coronary Artery Disease
This study is being conducted to determine if smoking will influence the platelet aggregation inhibition ability of clopidogrel and prasugrel.
- Trial name
- NCT01260584
- Testing
- Prasugrel, Clopidogrel
- Where
- 3 sites in United States
- Volunteers
- 110 people
- Sponsor
- Daiichi Sankyo
Heart Disease, Coronary, Chest Pain
The Computed Tomography-derived Fractional Flow Reserve STAT Trial
This study is designed to directly compare Standard Care and CT fractional flow reserve (CTFFR) for diagnosis of chest pain patients with definite coronary artery disease (CAD) on heart computed tomography (CT) scans.
- Conditions
- Heart Disease, Coronary, Chest Pain, Acute Coronary Syndrome
- Trial name
- CTFFR-STAT (NCT03263806)
- Testing
- CTFFR-Guided Group Management, SOC Group Management
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Corewell Health East
Coronary Artery Disease
Study of the Vascular Effects of Serelaxin
This was a mechanistic study in patients with coronary artery disease on the effects of Serelaxin on micro- and macrovascular function.
- Trial name
- NCT01979614
- Testing
- Serelaxin
- Where
- 3 sites in United Kingdom
- Volunteers
- 58 people
- Sponsor
- Novartis Pharmaceuticals
Coronary Artery Disease, Myocardial Ischemia
AngioSculpt® Coronary Bifurcation Study
The purpose of this study is to evaluate a new angioplasty catheter, AngioSculpt® for the treatment of bifurcation lesions (blockages occurring at branch points) in coronary arteries.
- Trial name
- AGILITY (NCT00686647)
- Testing
- AngioSculpt® Scoring Balloon Catheter, AngioSculpt Scoring Balloon Catheter
- Where
- United States
- Volunteers
- 93 people
- Sponsor
- AngioScore, Inc.
Coronary Artery Disease, Mitral Valve Regurgitation
Magna® Mitral Pericardial Bioprostheses Post-Approval Study Protocol
The purpose of the study is to demonstrate the long term safety and effectiveness of the Carpentier-Edwards® PERIMOUNT Magna Mitral Valves in patients undergoing mitral valve replacement with or without concomitant procedures…
- Conditions
- Coronary Artery Disease, Mitral Valve Regurgitation, Mitral Valve Incompetence, Heart Failure
- Trial name
- NCT00853632
- Testing
- CEP MAGNA MITRAL PERICARDIAL BIOPROSTHESES
- Where
- 15 sites in United States, Austria and 2 more
- Volunteers
- 329 people
- Sponsor
- Edwards Lifesciences
Coronary Artery Disease, Coronary Disease
Post-Market CorPath Registry on the CorPath 200 System in Percutaneous Coronary Interventions
To collect data on the routine patterns of use, safety and effectiveness, including the clinical and technical performance of the CorPath 200 System, in the delivery and manipulation of coronary guidewires and stent/balloon…
- Conditions
- Coronary Artery Disease, Coronary Disease, Myocardial Ischemia, Heart Diseases
- Trial name
- PRECISION (NCT01917682)
- Testing
- CorPath-assisted Percutaneous Coronary Intervention
- Where
- 16 sites in United States, Israel
- Volunteers
- 754 people
- Sponsor
- Siemens Healthineers Endovascular Robotics, Inc.